Replies to post #333446 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Blarcamesine treatment cost projections.

With those projected annual Rett syndrome treatment costs (revenues to Anavex), pull up your spreadsheet and start punching in numbers that might then apply for both Parkinson’s disease dementia and Alzheimer’s.

Lots of zeros.

A few of us with conservative cost projections have punched in projected $10/day blarcamesine costs for the millions with Alzheimer’s. Should we, now, increase that daily treatment cost?

Oh, wait. Missling’s telling of projected annual blarcamesine/Rett treatment costs (6 figures) must mean that the Parkinson’s disease dementia and Alzheimer’s trials are failing. Data won’t be good enough to get FDA approval. Therefore, Anavex will have to survive only on Rett revenues. [Sarc]